London, UK — 03 March 2025 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications.
The proposed indications are…
London, UK — 03 March 2025 — GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application for the use of depemokimab in two indications.
The proposed indications are…
No Comments
Leave a comment Cancel